Healius acknowledged the withdrawal of the off-market takeover offer by Australian Clinical Labs (ASX:ACL) for all fully paid ordinary shares in Healius.
Following the withdrawal, the 156,148,077 Healius shares issued through the recent non-renounceable entitlement offer, denoted as 'HLSNB,' will cease trading in that class on Dec. 22.
Healius' shares trading under HLSNB will be consolidated into HLS, effective Dec. 27.